Switch to oral hypoglycemic agent therapy from insulin injectio
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000007051
- Lead Sponsor
- Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Not provided
(1) had hypersensitivity or a contraindication to mitiglinide or sitagliptin; (2) had a history of type 1 diabetes or a history of ketoacidosis; (3) experienced repeated episodes of unexplained hypoglycaemia as defined by FPG or without the symptoms of hypoglycaemia or <60 mg/dl with symptoms of hypoglycaemia; (4) concomitantly suffering from infection and planning to have surgery; (5) treatment with a mitiglinide, and a sitagliptin within 12 weeks before screening; (6) concomitant corticosteroid therapy; (7) poorly controlled diabetes; (8) under dialysis and serum creatinine >2.5 mg/dl in men or >2.0 mg/dl in women; (9) alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) more than 2.5-fold the upper limit of normal; (10) poorly controlled hypertensions or systolic blood pressure>160 mmHg, or diastolic blood pressure>100 mmHg; (11) currently and/or previously suffering from heart failure; (12) severe retinopathy; (13) malignancy on active therapeutic regimen or without complete remission or cure; (14) pregnancy or breast feeding; (15) inadequacy to participate in the study, as assessed by the investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method